Health Care [ 9/12 ] | Biotechnology [ 26/73 ]
NASDAQ | Common Stock
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs.
The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology.
Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer.
The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment.
Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 9, 25 | -0.25 Increased by +99.96% | - |
| Mar 31, 25 | -1.72 Decreased by -300.00% | -0.14 Decreased by -1.13 K% |
| Nov 14, 24 | -1.75 Increased by +21.96% | -8.40 Increased by +79.19% |
| Jun 30, 24 | -3.30 Increased by +87.44% | -8.70 Increased by +62.07% |
| May 15, 24 | -664.20 Decreased by -237.11 K% | -52.80 Decreased by -1.16 K% |
| Mar 8, 24 | -0.43 Decreased by -86.96% | -0.25 Decreased by -72.00% |
| Nov 14, 23 | -2.24 Decreased by -229.41% | -8.17 Increased by +72.58% |
| Aug 14, 23 | -26.28 Decreased by -4.95 K% | -11.19 Decreased by -134.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 0.00 Decreased by -100.00% | -2.73 M Increased by +28.91% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 24 | 0.00 Decreased by -100.00% | -7.45 M Decreased by -332.81% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -12.15 M Decreased by -118.88% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.63 M Increased by +31.55% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 112.00 K Increased by +N/A% | -3.84 M Decreased by -22.35% | Decreased by -3.43 K% Decreased by N/A% |
| Dec 31, 23 | 112.00 K Increased by +N/A% | -1.72 M Increased by +39.32% | Decreased by -1.54 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.55 M Decreased by -10.22% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -2.38 M Increased by +48.89% | Decreased by N/A% Decreased by N/A% |